Biomea Fusion, Inc. (BMEA)
$0.83-34.13%Close
SELLCRISIS · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $60M
- Beta
- -0.30
- P/E (TTM)
- -1.68
- Short % float
- 20.88%
- Days to cover
- 5.7
- SI change
- +6.5%
- 1W
- -37.12%
- 1M
- -53.89%
- vs SPY 1W
- -36.14%
- vs SPY 1M
- -55.75%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 16
- GROWTH
- 47
- GARP
- 6
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-102.7%
REV YoY-
ROE-171.2%
EPS YoY-
ROA-88.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.68
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B4.97
P/FCF-
EV/EBITDA-0.77
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E7.23
ALTMAN Z-
CURR RATIO3.47
ND/EBITDA-
BETA-0.30
Company news
FAQ
- What is LOPJLB’s current signal on BMEA?
- LOPJLB’s latest quantitative signal on Biomea Fusion, Inc. (BMEA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BMEA in?
- Biomea Fusion, Inc. (BMEA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Biomea Fusion, Inc. (BMEA) do?
- Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. Itâs lead clinical programâs drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in P…